+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 70 Actively Recruiting clinical trials

I

Actively Recruiting

Researchers are creating a national registry in Italy to observe and record how multiple myeloma is diagnosed and treated in routine clinical practice. This observational study aims to describe the standard care for patients with multiple myeloma across different hematology centers, reflecting the current situation and variations in treatment and patient characteristics. Both retrospective and prospective data will be collected to provide a comprehensive view. The study involves a non-interventional, multicenter registry that includes patients diagnosed with multiple myeloma since January 1, 2019. Patients are enrolled consecutively during their routine appointments, and data are collected using an electronic platform. Patients participating in other studies may also be included, with baseline and survival data collected during their participation in interventional trials. Hospital visits for data collection occur approximately every six months. Participants will be followed for up to three years, during which researchers will measure overall survival and time to next treatment. Patient-reported outcomes and costs incurred by patients will also be tracked over this period. The study encourages patient involvement and aims to enhance understanding of multiple myeloma care in Italy without altering standard treatment or requiring additional interventions.

Age: 18Years +All Genders
27 locations
L

Actively Recruiting

Researchers are assessing the long-term safety of subcutaneous guselkumab in children with moderate to severe ulcerative colitis, Crohns disease, or juvenile psoriatic arthritis. This Phase 3, open-label study enrolls pediatric participants who previously received guselkumab in one of three primary studies and are considered by their investigator to benefit from continued treatment. The study aims to monitor safety over an extended period to better understand the effects of ongoing guselkumab use in these conditions. Participants who completed dosing in the primary studies will continue guselkumab treatment in this long-term extension study. Dosing schedules include injections every 8 weeks or every 4 weeks, depending on their original study arm and clinical status. Some participants may switch dosing intervals once during the study before unblinding, while others will maintain their initial regimen. The study allows continued access to guselkumab over the long term, with dosing adjustments guided by prior treatment plans and investigator discretion. Throughout the study, participants will be closely monitored for treatment-emergent adverse events for up to 6 years and 9 months. Assessments will include regular evaluations by investigators to ensure safety and adherence. Parents or legal representatives consent for children to participate, with assent obtained from capable participants aged 7 years and older. The study emphasizes long-term safety tracking and maintaining participant well-being during extended guselkumab therapy.

Age: 3Years +All GendersPhase 3
53 locations
E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
M

Actively Recruiting

Researchers are collecting and creating a labeled ultrasound image data set from patients undergoing routine ultrasound scans of their lower limbs due to suspected deep vein thrombosis DVT. This observational study aims to gather imaging data, patient information, and ultrasound metadata to train artificial intelligence AI models that can automatically detect DVT from conventional ultrasound scans. The study is part of the ThrombUS project, which focuses on developing tools for early and automated DVT diagnosis to improve patient safety and outcomes. The study involves selecting patients suspected of having DVT who are referred for ultrasound scans. These patients, both inpatients and outpatients, will be consecutively included to ensure diversity of demographics, medical conditions, and ultrasound operators. The collected data will include ultrasound image series and video clips, along with anonymized patient demographics, referral notes, medical conditions, scan diagnoses, operator IDs, and ultrasound equipment details. The anonymized data set will be prepared according to regulations for research use and shared publicly through European science portals. Participants will undergo routine ultrasound scans for suspected DVT, and their scan data and related information will be collected and anonymized. The primary outcome is the ultrasound data collected on the day of the scan. The data set will support AI model training and research, with the anonymized information made available for further study. Participation involves providing informed consent and allowing the inclusion of their scan data and metadata. The study will monitor data quality and maintain privacy throughout, with no interventional treatments involved.

Age: 18Years +All Genders
5 locations
P

Actively Recruiting

Researchers are conducting a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of three different dose regimens of MORF-057 in adults with moderately to severely active Crohns disease CD. The study aims to assess how well MORF-057 works compared to placebo during induction therapy in this patient population. The trial is conducted across multiple centers and includes adults aged 18 to 85 years with active CD as defined by clinical and endoscopic criteria. Participants will be randomly assigned to one of three blinded groups receiving different doses of MORF-057 or matching placebo during a 14-week Induction Period. Following this, all participants will receive open-label MORF-057 during a 38-week Maintenance Period. Those who complete the full 52-week treatment phase may continue treatment in a 52-week Long-Term Extension to further assess long-term effects. Throughout the study, participants will undergo assessments including the Simple Endoscopic Score for Crohns Disease SES-CD at week 14 to measure endoscopic response, and the Crohns Disease Activity Index CDAI to evaluate clinical response and remission. Safety and tolerability will be monitored regularly. The total study duration for participants can extend up to 104 weeks including the extension phase, with frequent visits and evaluations to monitor disease activity and treatment effects.

Age: 18Years - 85YearsAll GendersPhase 2
224 locations
P

Actively Recruiting

Researchers are evaluating HLX22 combined with trastuzumab and chemotherapy as a first-line treatment for patients with HER2-positive locally advanced or metastatic adenocarcinoma of the gastric or gastroesophageal junction. This phase 3, randomized, double-blind study compares this combination against trastuzumab plus chemotherapy with or without pembrolizumab. The trial aims to assess the efficacy and safety of adding HLX22 in this patient population. Participants will be randomly assigned in a 11 ratio to either the experimental group receiving HLX22 15 mgkg plus trastuzumab and chemotherapy XELOX with or without a placebo for pembrolizumab every three weeks, or the control group receiving placebo for HLX22 plus trastuzumab and chemotherapy XELOX with or without pembrolizumab also every three weeks. Treatment continues until clinical benefit is lost, intolerable side effects occur, death, withdrawal, or other protocol-specified reasons. Throughout the study, participants will have their disease progression monitored by an independent radiology review committee using RECIST v1.1 criteria for up to five years, along with overall survival and response rates. Safety will be regularly assessed by tracking adverse events. The study includes multiple assessments to evaluate treatment effects, and participants will be followed for long-term outcomes during the trial period.

Age: 18Years +All GendersPhase 3
208 locations
R

Actively Recruiting

Researchers are evaluating a new approach to selecting biologic treatments for adults with active Crohns Disease CD. This prospective, randomized study compares standard treatment selection to a method guided by epigenetic markers, aiming to assess which method better induces clinical remission and improves endoscopic response. The trial includes patients who are either new to biologic therapy or have used no more than one prior biologic treatment. The study is designed to measure efficacy, safety, and cost-effectiveness of this epigenome-guided approach. Participants are randomly assigned to one of two groups one receives biologic therapy based on epigenetic testing results using a specialized software called EpiPredict, which predicts response to two biologics, Vedolizumab VDZ or Ustekinumab UST. The other group receives biologic treatment chosen by their doctor following usual care guidelines without epigenetic information. Both groups receive their biologic treatments as labeled, with dosing adjustments allowed as needed by the treating physician. Throughout the 26-week treatment phase, participants undergo clinical assessments aligned with their biologic treatment schedules. Follow-up visits continue every six months up to two years, collecting data from medical records and online questionnaires. Researchers will measure clinical remission, endoscopic response, and cost-effectiveness among other outcomes to determine the value of using epigenetic markers in treatment selection for Crohns Disease.

Age: 18Years +All GendersPhase Not Applicable
51 locations
C

Actively Recruiting

This trial investigates treatments for adults with relapsed or refractory multiple myeloma who have already received at least three prior therapies, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. Researchers are comparing the effects of a new drug called JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody called teclistamab. The goal is to evaluate how well JNJ-79635322 works in comparison to the existing antibody treatment. Participants will be randomly assigned to receive either JNJ-79635322 or teclistamab, both given as subcutaneous injections. Treatments will continue until the disease progresses or participants experience intolerable side effects. The study is designed as a phase 3 trial, with treatment lasting potentially up to several years depending on individual response and tolerance. During the trial, participants will have regular assessments to monitor response to treatment, disease progression, side effects, and quality of life. Measures include overall response, progression-free survival, complete response rates, symptom and functioning questionnaires, and laboratory tests. Safety is closely monitored, along with drug levels and immune responses. The total participation period may last up to five years and seven months, with ongoing evaluations throughout this time.

Age: 18Years +All GendersPhase 3
157 locations
P

Actively Recruiting

Researchers are evaluating the drug efruxifermin EFX in adults with compensated cirrhosis caused by NASH Nonalcoholic Steatohepatitis or MASH Metabolic Dysfunction-Associated Steatohepatitis. This phase 3, randomized, double-blind, placebo-controlled study aims to assess the safety and efficacy of EFX in slowing disease progression and improving liver health over several years. Participants will be randomly assigned to receive either EFX 50 mg or a placebo, both given by subcutaneous injection. The study includes two cohorts one with biopsy-proven compensated cirrhosis and metabolic features, and another diagnosed either by biopsy or non-invasive methods. Treatment and follow-up will continue for up to five years to monitor outcomes. Throughout the study, participants will undergo regular assessments including liver fibrosis markers, liver injury markers, lipoproteins, insulin sensitivity, glycemic control, and body weight changes. Safety will be closely monitored through laboratory tests, ECGs, ultrasounds, and vital signs. The primary outcome measures include time to significant clinical events like disease progression or liver decompensation and improvements in fibrosis and steatohepatitis, with follow-up extending up to five years.

Age: 18Years - 80YearsAll GendersPhase 3
345 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of efruxifermin EFX in adults with non-cirrhotic nonalcoholic steatohepatitis NASH or metabolic dysfunction-associated steatohepatitis MASH who have moderate to advanced liver fibrosis stage 2 or 3. This Phase 3, multi-center study randomly assigns participants to different treatment groups and compares EFX with a placebo to see its impact on liver health and related clinical outcomes. Participants are divided into two groups one with about 750 subjects having confirmed NASHMASH and fibrosis stage 2 or 3, and another with about 900 subjects with fibrosis stage 3 regardless of their NAFLD activity score. They receive either 28 mg or 50 mg of EFX or a matching placebo through weekly injections under the skin. The study includes a screening period up to 12 weeks, a 52-week treatment phase for the first group, a 96-week phase for the second group, and an extended follow-up period lasting up to around 240 weeks, plus a follow-up visit about a month after the last dose. During the study, participants undergo liver biopsies, blood tests, imaging scans like FibroScan, and assessments of liver fibrosis markers and metabolism-related measures. Researchers monitor changes in liver tissue, liver function tests, cholesterol, blood sugar control, body weight, and safety indicators over time. Even if participants stop the study drug early, they may continue with scheduled assessments to support long-term evaluation of treatment effects and safety throughout the study duration.

Age: 18Years - 80YearsAll GendersPhase 3
359 locations

1-10 of 70

1